Pfizer’s RSV Vaccine Candidate Looks Promising

  Vidcast:  https://youtu.be/Sa0ZVTidyJk   Pfizer’s RSV vaccine, called RSVpreF, generates antibodies against the fusion protein that the RSV virus uses to enter human respiratory cells.  The vaccine is designed to be administered to pregnant women who produce antibodies against the fusion protein that pass across the placenta to their developing babies.  The antibodies then protect the newborns against RSV for their first 6 months when they are most vulnerable.  The ongoing Phase 3 study of some 7400 pregnant women so far reveals 82% protection against severe RSV during a baby’s first 3 months and an overall 69% protection level over the first 6 months.  Expect an FDA application by the end of 2022.   https://www.businesswire.com/news/home/20221101005117/en/Pfizer-Announces-Positive-Top-Line-Data-of-Phase-3-Global-Maternal-Immunization-Trial-for-its-Bivalent-Respiratory-Syncytial-Virus-RSV-Vaccine-Candidate   #pfizer #rsv #vaccine #newborns #fusion